Natural Capsules Reports Mixed Q1 Results: Standalone Profit Amid Consolidated Loss

Natural Capsules , a leading pharmaceutical company, has reported mixed financial results for the first quarter. The company's standalone performance showed growth, while its consolidated results reflected challenges in its API segment.

Standalone Performance

On a standalone basis, Natural Capsules demonstrated resilience with a revenue from operations of Rs 44.24 crore. The company reported a net profit of Rs 2.52 crore, translating to an earnings per share (EPS) of Rs 2.44.

Consolidated Results

The consolidated financial picture, however, painted a different story. While the consolidated revenue stood at Rs 45.20 crore, the company reported a net loss of Rs 5.58 crore, resulting in a negative EPS of Rs 5.40.

Segment-wise Performance

The company's financial results revealed a stark contrast between its two main segments:

1. Capsules Segment: This segment remained profitable, contributing Rs 44.24 crore to the revenue and generating a profit of Rs 4.84 crore before tax and interest.

2. API Segment: The newly operational API segment reported a revenue of Rs 96.02 lakh but incurred a significant loss of Rs 6.99 crore before tax and interest.

Subsidiary Operations

Natural Biogenex Private Limited, a subsidiary of Natural Capsules, commenced commercial operations on March 31, 2025. The company noted that the subsidiary is still in the process of achieving its full revenue potential, which contributed to the consolidated loss.

Management Commentary

Mr. Sunil L Mundra, Managing Director of Natural Capsules Limited, stated, "While our standalone performance remains strong, we are navigating challenges in our API segment. The loss in this segment is primarily due to our subsidiary, Natural Biogenex Private Limited, which is in its early stages of commercial operations. We are confident that as the subsidiary ramps up its operations, it will positively contribute to our consolidated results in the coming quarters."

Corporate Governance

The company's board has designated Mr. Sunil L Mundra as the Managing Director for determining the materiality of events, and Ms. Pranjal Deshmukh as the Company Secretary for disclosure submissions, in compliance with SEBI regulations.

Outlook

Despite the consolidated loss, Natural Capsules remains optimistic about its future prospects. The management expects the API segment to improve its performance as operations stabilize and scale up in the coming quarters.

Investors and stakeholders will be closely watching the company's performance in subsequent quarters, particularly the progress of its API segment and the subsidiary's contribution to the overall financial health of the company.

Natural Capsules continues to focus on its core competencies while navigating the challenges in its new ventures. The company's ability to turn around its consolidated performance will be crucial for its growth trajectory in the pharmaceutical sector.